Skip to Main content Skip to Navigation
Journal articles

Subtype and pathway specific responses to anticancer compounds in breast cancer.

Laura M Heiser 1 Anguraj Sadanandam 1 Wen-Lin Kuo 1 Stephen C Benz 2, 3 Theodore C Goldstein 2, 3 Sam Ng 2, 3 William J Gibb 1 Nicholas J Wang Safiyyah Ziyad 1 Frances Tong 4 Nora Bayani 1 Zhi Hu 1 Jessica I Billig 1 Andrea Dueregger 1 Sophia Lewis 1 Lakshmi Jakkula 1 James E Korkola 1 Steffen Durinck 1 François Pepin 1 yinghui Guan 1 Elizabeth Purdom 4 Pierre Neuvial 5, 4 Henrik Bengtsson 4, 6 Kenneth W Wood 7 Peter G Smith 8 Lyubomir T Vassilev 9 Bryan T Hennessy 10 Joel Greshock 11 Kurtis E Bachman 11 Mary Ann Hardwicke 11 John W Park 12 Laurence J Marton 13 Denise M Wolf 1 Eric A Collisson 12 Richard M Neve 1 Gordon B Mills 10 Terence P Speed 14, 4 Heidi S Feiler 1 Richard F Wooster 11 David Haussler 15 Joshua M Stuart 2, 3 Joe W Gray 16 Paul T Spellman 1 
Abstract : Breast cancers are comprised of molecularly distinct subtypes that may respond differently to pathway-targeted therapies now under development. Collections of breast cancer cell lines mirror many of the molecular subtypes and pathways found in tumors, suggesting that treatment of cell lines with candidate therapeutic compounds can guide identification of associations between molecular subtypes, pathways, and drug response. In a test of 77 therapeutic compounds, nearly all drugs showed differential responses across these cell lines, and approximately one third showed subtype-, pathway-, and/or genomic aberration-specific responses. These observations suggest mechanisms of response and resistance and may inform efforts to develop molecular assays that predict clinical response.
Complete list of metadata
Contributor : Pierre Neuvial Connect in order to contact the contributor
Submitted on : Thursday, September 17, 2015 - 3:27:19 PM
Last modification on : Tuesday, May 31, 2022 - 10:20:15 AM

Links full text




Laura M Heiser, Anguraj Sadanandam, Wen-Lin Kuo, Stephen C Benz, Theodore C Goldstein, et al.. Subtype and pathway specific responses to anticancer compounds in breast cancer.. Proceedings of the National Academy of Sciences of the United States of America, National Academy of Sciences, 2012, 109 (8), pp.2724-9. ⟨hal-01201568⟩



Record views